Search

Your search keyword '"Coustal, Cyrille"' showing total 12 results
Start Over Author "Coustal, Cyrille"
12 results on '"Coustal, Cyrille"'

3. Time to use the right classification to predict the severity of checkpoint inhibitor‐induced liver injury, as assessed for causality using the updated RUCAM.

Author

Hountondji, Lina, Faure, Stéphanie, Palassin, Pascale, Viel, Philine Witkowski Durand, Dupuy, Marie, Larrey, Dominique, Lamoureux, Anouck, Coustal, Cyrille, Pureur, Dimitri, Lesage, Candice, Assenat, Éric, Rivière, Benjamin, Faillie, Jean‐Luc, Quantin, Xavier, Pageaux, Georges‐Philippe, Maria, Alexandre Thibault Jacques, and Meunier, Lucy

Subjects
IMMUNE checkpoint inhibitors, LIVER injuries, LIVER diseases, UNIVERSITY hospitals, CANCER treatment
Abstract

Summary: Background and Aims: While immune checkpoint inhibitors (ICIs) are revolutionising cancer therapy, checkpoint inhibitor‐induced liver injury is a significant immune‐related side effect of this immunotherapy. This study focuses on the severity classifications and characteristics of patients with checkpoint inhibitor‐induced hepatitis. Methods: A retrospective analysis of patients with severe Checkpoint Inhibitor‐induced hepatitis grade 3 and 4 according to the recommended Common Terminology Criteria for Adverse Events (CTCAE) classification was conducted. Data on clinicobiological characteristics, treatment and outcomes were collected from 3 university hospitals, and causality was assessed by using the updated Roussel Uclaf Causality Assessment Method. The severity of hepatitis was assessed using the Model for End‐stage Liver Disease score, the Drug‐Induced Liver Injury Network, and the Drug‐Induced Liver Injury International Expert Working Group classifications. Results: We retrospectively included 100 patients presenting various hepatitis patterns with a median time to onset of 20 days after checkpoint inhibitors. Severity grading varied significantly among the classifications used. A lower incidence of severe cases was observed when using the Drug‐Induced Liver Injury classifications instead of the recommended CCTCAE classification, and this was correlated with outcomes. Conclusions: This retrospective study challenges the efficacy of the CTCAE classification in defining the severity of Checkpoint Inhibitor‐induced hepatitis and suggests that the traditional hepatology‐focused scores may be more relevant. The CTCAE classification is inconsistent and gives equal weight to jaundice and elevated transaminases, which leads to steroid overtreatment and limits the rechallenge of ICIs. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX.

Author

Hadjadj, Jerome, Yann Nguyen, Mouloudj, Dalila, Bourguiba, Rim, Heiblig, Mael, Aloui, Hassina, McAvoy, Chloe, Lacombe, Valentin, Ardois, Samuel, Campochiaro, Corrado, Maria, Alexandre, Coustal, Cyrille, Comont, Thibault, Lazaro, Estibaliz, Lifermann, Francois, Guenno, Guillaume Le, Lobbes, Hervé, Grobost, Vincent, Outh, Roderau, and Campagne, Julien

Published
2024
Full Text
View/download PDF

6. Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series

Author

Coustal, Cyrille, primary, Vanoverschelde, Juliette, additional, Quantin, Xavier, additional, Lesage, Candice, additional, Michot, Jean-Marie, additional, Lappara, Ariane, additional, Ederhy, Stephane, additional, Assenat, Eric, additional, Faure, Maxime, additional, Issa, Nahema, additional, Lambotte, Olivier, additional, Puyade, Mathieu, additional, Dereure, Olivier, additional, Tosi, Diego, additional, Rullier, Patricia, additional, Serre, Isabelle, additional, Larcher, Romaric, additional, Klouche, Kada, additional, Chanques, Gérald, additional, Vernhet-Kovacsik, Hélène, additional, Faillie, Jean-Luc, additional, Agullo, Audrey, additional, Roubille, François, additional, Guilpain, Philippe, additional, and Maria, Alexandre Thibault Jacques, additional

Published
2023
Full Text
View/download PDF

8. Clinical, Radiologic, and Immunologic Features of Patients With CTLA4 Deficiency With Neurologic Involvement.

Author

Coustal, Cyrille, Goulabchand, Radjiv, Labauge, Pierre, Guilpain, Philippe, Carra-Dallière, Clarisse, Januel, Edouard, Jeziorski, Eric, Salle, Valery, Viallard, Jean-François, Boutboul, David, Fieschi, Claire, Gobert, Delphine, Aladjidi, Nathalie, Rullier, Patricia, Graveleau, Julie, Piel-Julian, Marie, Suarez, Felipe, Neven, Benedicte, Mahlaoui, Nizar, and Ayrignac, Xavier

Published
2023
Full Text
View/download PDF

12. Azacitidine for Patients with Vexas Syndrome: Data from the French Vexas Registry

Author

Comont, Thibault, Kosmider, Olivier, Heiblig, Mael, Terrier, Benjamin, Bouscary, Didier, Le Guenno, Guillaume, Outh, Roderau, Samson, Maxime, Aouba, Achille, Lazarro, Estibaliz, Rauzy, Odile, Rigolot, Lucie, Peterlin, Pierre, Maria, Alexandre, Flammarion, Edouard, Garnier, Alice, De Renzis, Benoit, Natarajan, Shanti, Carpentier, Benjamin, Roux-Sauvat, Marielle, Torregrosa, Jose, Closs-Prophette, Fabienne, Rossignol, Julien, Schleinitz, Nicolas, Dieval, Celine, Broner, Jonahan, Gourin, Marie-Pierre, Sauvetre, Gaetan, Faucher, Benoit, Vinit, Julien, Grosleron, Sylvie, Mathian, Alexis, Terriou, Louis, Coustal, Cyrille, Guilpain, Philippe, Marianetti-Guingel, Paola, Bezanahary, Holy, Vey, Norbert, Mohty, Bilal, Moulinet, Thomas, Grobost, Vincent, Dimicoli, Sophie, Suzon, Benoit, Perlat, Antoinette, Hirsh, Pierre, Larcher, Lise, Zhao, Lin Pierre, Georgin-Lavialle, Sophie, Mekinian, Arsene, Fenaux, Pierre, Jachiet, Vincent, VEXAS study group, French, French Network of immune disorders associated with hemopathies, Minhemon, and Groupe Francophone des Myélodysplasies, GFM

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results